ASX Code: MEM



ASX Release 13 July 2023

Memphasys granted two new Australian Patents for the Felix[™] System

Australian-based reproductive biotechnology company, Memphasys Limited (ASX: MEM), announce that it has been granted two new patents for the Felix[™] System (Felix[™]) by the Australian Patent Office. These two new patents enhance MEM's patent portfolio and ensure the value and integrity of the Felix[™] device is properly protected in all markets.

Felix[™] is an automated device with a single-use cartridge that gently separates high-quality sperm from a semen sample in six minutes using electrophoresis for use in human IVF procedures. Felix[™] is MEM's first commercial product.

Details of the patents are as follows:

Title of invention	Electrophoresis device
Patent number	2017344755
Date of grant	18 May 2023
Term of patent	20 years from 20 October 2017
Existing patents (by jurisdiction)	China, Japan, the United States; European Union (pending)
Title of invention	Sperm separation by electrophoresis
Patent number	2017344756
Date of grant	20 years from 20 October 2017
Existing patents (by jurisdiction)	China, Japan, the United States; European Union (pending)

MEM Chief Executive Officer, Ms Alison Coutts, said 'The patents are essential to protecting MEM's unique intellectual property globally.'

This announcement has been approved for release by the board of Memphasys Limited.

ENDS

For further information, please contact: Alison Coutts Managing Director / Chief Executive Officer Memphasys Limited Tel: +61 2 8415 7300 E: alison.coutts@memphasys.com

David Tasker Managing Director Chapter One Advisors Tel: +61 433 112 936 E: <u>dtasker@chapteroneadvisors.com.au</u>

About Memphasys

Memphasys Limited (ASX: MEM) specialises in reproductive biotechnology for high value commercial applications. Reproductive biotechnology products in development include medical devices, *in vitro* diagnostics, and new proprietary media. The Company's patented bio-separation technology, utilised by the Company's most advanced product, the Felix[™] System device, combines electrophoresis with proprietary size exclusion membranes to separate the most viable sperm cells for human artificial reproduction.

Website: www.memphasys.com

The Felix[™] System is a registered trademark of Memphasys Limited. All rights reserved.